Results 21 to 30 of about 143,581 (292)

Anticoagulants for acute ischaemic stroke [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Counsell, Carl   +2 more
core   +1 more source

Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique

open access: yesHaematologica, 2013
Pulmonary embolism is considered to originate from embolization of a deep-vein thrombosis, resulting in two manifestations of one disease: venous thrombosis.
Kirsten van Langevelde   +5 more
doaj   +1 more source

Venous Thromboembolism Within Professional American Sport Leagues. [PDF]

open access: yes, 2017
Background: Numerous reports have described players in professional American sports leagues who have been sidelined with a deep vein thrombosis (DVT) or a pulmonary embolism (PE), but little is known about the clinical implications of these events in ...
Astolfi, Matthew   +4 more
core   +2 more sources

The Incidence of Deep Vein Thrombosis after Hip and Knee Arthroplasties in Japanese Patients: A Prospective Study

open access: yesJournal of Orthopaedic Surgery, 2003
Purpose. To document the incidence of proximal deep vein thrombosis and pulmonary embolism in 58 consecutive Japanese patients undergoing total hip arthroplasty or total knee arthroplasty. Methods.
A Sudo   +5 more
doaj   +1 more source

Pulmonary embolism caused by ovarian vein thrombosis during cesarean section: a case report

open access: yesJA Clinical Reports, 2018
Background Ovarian vein thrombosis is a rare complication of pregnancy. The representative complaints of patients with ovarian vein thrombosis are abdominal pain and fever. In some cases, however, fatal pulmonary embolism may develop. We report a case of
Yutaka Oda   +5 more
doaj   +1 more source

Extended thromboprophylaxis with betrixaban in acutely ill medical patients [PDF]

open access: yes, 2016
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
. Lodigiani, M   +18 more
core   +1 more source

Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study

open access: yesHaematologica, 2010
The term factor V Leiden (FVL) paradox is used to describe the different risk of deep vein thrombosis and pulmonary embolism that has been found in carriers of FVL. In a thrombophilic family-cohort, we estimated differences in absolute risks of deep vein
Anja B.U. Mäkelburg   +6 more
doaj   +1 more source

Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study

open access: yesBMJ Open, 2020
Objectives To evaluate the short-term (12 weeks) safety and utilisation of rivaroxaban prescribed to new-user adult patients for the treatment of deep vein thrombosis and pulmonary embolism and for the prevention of recurrent deep vein thrombosis and ...
Vicki Osborne   +4 more
doaj   +1 more source

Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]

open access: yes, 2018
It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P   +5 more
core   +1 more source

Efficacy, Safety, and Timing of Anticoagulant Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Systematic Review [PDF]

open access: yes, 2017
Study Design: Systematic review. Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a) anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another ...
Arnold, Paul M.   +10 more
core   +2 more sources

Home - About - Disclaimer - Privacy